Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GERN NASDAQ:IOVA NASDAQ:ORIC NASDAQ:THRD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGERNGeron$1.40-2.1%$1.35$1.09▼$4.83$893.22M0.7310.13 million shs3.41 million shsIOVAIovance Biotherapeutics$2.23$2.34$1.64▼$12.51$806.93M0.8815.36 million shs7.02 million shsORICOric Pharmaceuticals$10.23+2.0%$10.38$3.90▼$14.67$974.14M1.69763,636 shs711,532 shsTHRDThird Harmonic Bio$5.38$0.00$0.00▼$0.00$242.80M2.12247,013 shsN/AA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGERNGeron-2.10%-4.11%+27.27%-9.39%-68.96%IOVAIovance Biotherapeutics0.00%-17.10%-16.48%+27.28%-80.32%ORICOric Pharmaceuticals+1.99%+5.03%-4.48%+23.85%+0.59%THRDThird Harmonic Bio0.00%0.00%-0.09%+3.26%-54.52%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGERNGeron3.0574 of 5 stars3.31.00.01.32.31.70.6IOVAIovance Biotherapeutics4.5446 of 5 stars4.24.00.04.21.62.50.6ORICOric Pharmaceuticals4.7378 of 5 stars4.53.00.04.42.63.30.6THRDThird Harmonic BioN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGERNGeron 2.56Moderate Buy$4.19199.11% UpsideIOVAIovance Biotherapeutics 2.36Hold$11.90433.63% UpsideORICOric Pharmaceuticals 2.90Moderate Buy$17.6372.29% UpsideTHRDThird Harmonic Bio 2.00Hold$5.00-7.06% DownsideCurrent Analyst Ratings BreakdownLatest THRD, ORIC, IOVA, and GERN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/19/2025IOVAIovance BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.008/14/2025ORICOric PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$20.00 ➝ $17.008/14/2025ORICOric PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $19.008/13/2025ORICOric PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.008/12/2025IOVAIovance BiotherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold8/12/2025ORICOric PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold8/8/2025IOVAIovance BiotherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$18.00 ➝ $14.008/8/2025IOVAIovance BiotherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$25.00 ➝ $20.007/23/2025IOVAIovance BiotherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.007/15/2025IOVAIovance BiotherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeNeutral ➝ Sell7/10/2025GERNGeronThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSell$1.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGERNGeron$164.45M5.43N/AN/A$0.41 per share3.41IOVAIovance Biotherapeutics$164.07M4.92N/AN/A$1.93 per share1.16ORICOric PharmaceuticalsN/AN/AN/AN/A$3.34 per shareN/ATHRDThird Harmonic BioN/AN/AN/AN/A$6.33 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGERNGeron-$174.57M-$0.13N/AN/AN/A-53.52%-31.37%-16.01%11/6/2025 (Estimated)IOVAIovance Biotherapeutics-$372.18M-$1.23N/AN/AN/A-161.44%-52.87%-41.31%11/6/2025 (Estimated)ORICOric Pharmaceuticals-$127.85M-$1.89N/AN/AN/AN/A-51.75%-47.09%11/11/2025 (Estimated)THRDThird Harmonic Bio-$45.47M-$0.62N/AN/AN/AN/A-19.27%-18.67%N/ALatest THRD, ORIC, IOVA, and GERN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ORICOric Pharmaceuticals-$0.46-$0.47-$0.01-$0.47N/AN/A8/7/2025Q2 2025IOVAIovance Biotherapeutics-$0.29-$0.33-$0.04-$0.33$67.14 million$59.95 million8/6/2025Q2 2025GERNGeron-$0.03-$0.02+$0.01-$0.02$47.30 million$49.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGERNGeronN/AN/AN/AN/AN/AIOVAIovance BiotherapeuticsN/AN/AN/AN/AN/AORICOric PharmaceuticalsN/AN/AN/AN/AN/ATHRDThird Harmonic BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGERNGeron0.467.876.79IOVAIovance BiotherapeuticsN/A3.272.89ORICOric PharmaceuticalsN/A16.1316.13THRDThird Harmonic BioN/A54.1054.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGERNGeron73.71%IOVAIovance Biotherapeutics77.03%ORICOric Pharmaceuticals95.05%THRDThird Harmonic Bio93.95%Insider OwnershipCompanyInsider OwnershipGERNGeron7.42%IOVAIovance Biotherapeutics10.30%ORICOric Pharmaceuticals6.82%THRDThird Harmonic Bio7.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGERNGeron229638.02 million590.68 millionOptionableIOVAIovance Biotherapeutics500361.85 million324.58 millionOptionableORICOric Pharmaceuticals8097.12 million90.50 millionOptionableTHRDThird Harmonic BioN/A45.13 million41.61 millionOptionableTHRD, ORIC, IOVA, and GERN HeadlinesRecent News About These CompaniesThird Harmonic Bio to Delist from NasdaqJuly 31, 2025 | tipranks.comThird Harmonic Bio, Inc. (THRD) Cash Flow - Yahoo FinanceJuly 11, 2025 | finance.yahoo.comThird Harmonic Bio Stock (NASDAQ:THRD), Insider Trading ActivityJuly 11, 2025 | benzinga.comThird Harmonic Bio Inc News (THRD) - Investing.comJuly 3, 2025 | investing.comThird Harmonic Bio Announces Stockholder Approval of Plan of Liquidation and Dissolution, Updated THB335 Phase 1 Clinical Data, and Initiation of Sale of THB335June 12, 2025 | globenewswire.comNortheast Dominates 2025 Highest Income Rankings, Study Says: See Where Your State StandsJune 9, 2025 | msn.comThird Harmonic Bio plans to liquidate the company, sell urticaria treatmentApril 14, 2025 | msn.comThird Harmonic Bio Announces Liquidation Plan: Stock Skyrockets 39% Pre-Market, But Retail’s ShatteredApril 14, 2025 | msn.comThird Harmonic Bio Announces Plan of Liquidation and DissolutionApril 14, 2025 | globenewswire.comThird Harmonic Bio Announces Fourth Quarter and Full Year 2024 Financial ResultsMarch 27, 2025 | globenewswire.comThird Harmonic Bio, Inc. (THRD) Loses -31.61% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerMarch 4, 2025 | zacks.comThird Harmonic Bio, Inc. (THRD) Upgraded to Buy: What Does It Mean for the Stock?February 14, 2025 | zacks.comDown -39.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Third Harmonic Bio, Inc. (THRD)February 14, 2025 | zacks.comThird Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic UpdateFebruary 11, 2025 | globenewswire.comThird Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx ConferenceNovember 25, 2024 | globenewswire.comApple making foray into smart home IP camera market, says analyst Ming-Chi KuoNovember 13, 2024 | finance.yahoo.comUpdates to the British Virgin Islands Anti-Money Laundering regime and changes for MLROsNovember 12, 2024 | jdsupra.comWall Street Analysts Believe Third Harmonic Bio, Inc. (THRD) Could Rally 26.67%: Here's is How to TradeNovember 11, 2024 | zacks.com(LEAD) Netmarble swings to black in Q3 on steady-selling titlesNovember 8, 2024 | msn.comNissan plans 9,000 job cuts, slashes annual profit outlookNovember 7, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesJoby Aviation: Why a Historic Flight Outweighs Analyst DowngradesBy Jeffrey Neal Johnson | August 19, 2025Mercury Systems Up 27%: Financials Send Investors a Clear SignalBy Jeffrey Neal Johnson | August 14, 2025Equal Weight ETFs: Hidden Upside in Today’s MarketBy Gabriel Osorio-Mazilli | August 23, 2025Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick?By Chris Markoch | August 28, 2025MarketBeat Week in Review – 08/18 - 08/22By MarketBeat Staff | August 23, 2025THRD, ORIC, IOVA, and GERN Company DescriptionsGeron NASDAQ:GERN$1.40 -0.03 (-2.10%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.42 +0.02 (+1.71%) As of 08/29/2025 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Iovance Biotherapeutics NASDAQ:IOVA$2.23 0.00 (0.00%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.25 +0.02 (+0.90%) As of 08/29/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.Oric Pharmaceuticals NASDAQ:ORIC$10.23 +0.20 (+1.99%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$10.23 0.00 (0.00%) As of 08/29/2025 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Third Harmonic Bio NASDAQ:THRDTF Financial Corporation is a savings and loan holding company. The Company's direct and indirect subsidiaries include Third Federal Bank (the Bank), Teragon Financial Corporation, Penns Trail Development Corporation and Third Delaware Corporation. The Bank is a community oriented Pennsylvania stock savings bank offering a variety of financial services to meet the needs of the communities it serves. As of December 31, 2011 the Bank operated fourteen branch offices in Bucks and Philadelphia Counties, Pennsylvania and in Mercer County, New Jersey. During the year ended December 31, 2011, the Company's subsidiary, TF Investments Corporation merged into TF Financial Corporation. In July 2013, the Company acquired Roebling Financial Corp, Inc. (Roebling) and its wholly-owned subsidiary, Roebling Bank. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
